Select some options

Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.

First published: 2022 Dec

Journal: Clinical Pharmacology in Drug Development

Authors: Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V

Paradigmenwechsel in der Glukosekontrolle: Urin-, Blut-, interstitielle Glukosemessung.

First published: 2022 Nov

Journal: Diabetologie und Stoffwechsel

Authors: Forst T

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.

First published: 2022 Nov

Journal: Scientific Reports

Authors: Fontes MSC, Dingemanse J, Halabi A, Tomaszewska-Kiecana M, Sidharta PN

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.

First published: 2022 Oct

Journal: ERJ Open Research

Authors: Maher TM, Schlecker C, Luedtke D, Bossert S, Zoz DF, Schultz A.

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

First published: 2022 Oct

Journal: British Journal of Clinical Pharmacology

Authors: Klein S, Gashaw I, Baumann S, Chang X, Hummel T, Thuß U, Friedrich C

New strategies to improve clinical outcomes for diabetic kidney disease.

First published: 2022 Oct

Journal: BMC Medicine

Authors: Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, Halabi A, Schnell O, Streckebein M, Tuttle KR

Diabetes Mellitus and the Heart.

First published: 2022 Sep

Journal: Experimental and Clinical Endocrinology & Diabetes

Authors: Schütt K, Forst T, Birkenfeld AL, Zirlik A, Müller-Wieland D, Marx N

Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel

First published: 2022 Aug

Journal: Clinical and Translational Science

Authors: Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J.

100 Jahre Insuline Vergangenheit – Gegenwart – Zukunft / Insuline: Was können sie – worauf hoffen wir?

First published: 2022 Jul

Journal: diabetes-online

Authors: Forst T.

Pharmacokinetics, pharmacodynamics, and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.

First published: 2022 Jul

Journal: British Journal of Clinical Pharmacology

Authors: Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F.

Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials

First published: 2022 Jul

Journal: Journal of Diabetes Science and Technology

Authors: Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O.

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

First published: 2022 May

Journal: Journal of Thrombosis and Haemostasis

Authors: Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects.

First published: 2022 Apr

Journal: Frontiers in Pharmacology

Authors: Hoerr R, Zimmermann A, Seitz F, Dienel A

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.

First published: 2022 Apr

Journal: Cardiovascular Diabetology

Authors: Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J. L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. Rodbard, Giuseppe M. C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra‑Maria Schumm‑Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl

Pharmacokinetics, Safety, and Tolerability of the α2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects.

First published: 2022 Mar

Journal: Clinical Pharmacology in Drug Development

Authors: Kapsa S, Thuss U, Boxnick S, Schaumann F, Schultz A, Unger S, Otto C